Fig. 3
From: Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015
Quarterly numbers of patients initiating treatment with DAA-based regimens, France, 2011–2015
Q: quarter, BOC: boceprevir, TVR: telaprevir, SOF: sofosbuvir, SMV: simeprevir, DCV: daclatasvir, LDV: ledipasvir, OBV: ombitasvir, PTVr: ritonavir-boosted paritaprevir, DSV: dasabuvir